2018³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2018-09-07±³À°ÀÏÀÚ : 2018-09-07
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¿Ü ´ëȸÀÇ½Ç 2°³·ë
±³À°ÁÖÁ¦ :
2018³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï-Àü°øÀÇ 30,000¿ø/Àü¹®ÀÇ 50,000¿ø ÇöÀåµî·Ï-Àü°øÀÇ 40,000¿ø/Àü¹®ÀÇ 60,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 09:30~10:30 ³²ÀÚ¿¡°Õ º¸ÀÌÁö ¾Ê´Â Áø½Ç ¹Ú¼±È(³²ÀÚ¿¡°Õ º¸ÀÌÁö ¾Ê¾Æ)
ÈÞ½Ä 09¿ù 07ÀÏ 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 10:50~11:15 Anatomy Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 11:15~11:40 Neurotransmitters ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 11:40~12:00 Function À̰Ǽ®(°³²À»Áöº´¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 10:50~11:15 Serotonergic system dysfunction ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 11:15~11:40 Noradrenergic system dysfunctio È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 11:40~12:00 HPA axis ¼ÛÈĸ²(¸íÁöº´¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 12:00~12:30 Effectiveness of aripiprazole from acute to maintenance treatment ³²¹ü¿ì(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 12:30~13:00 Do patients benefit from aripiprazole once monthly on the aspect of QoL and functioning ¹èÄ¡¿î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 12:00~12:30 Differential impact of benzodiazepines and buspirone ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 12:30~13:00 ÁÖ¿ä¿ì¿ïÁõ ȯÀÚÀÇ somatization°ú cognitive dysfunctionÀÇ È£ÀüÀ» À§ÇÑ buspirone augmentation È¿°ú À̽Âȯ(ÀÎÁ¦ÀÇ´ë)
ÈÞ½Ä 09¿ù 07ÀÏ 13:00~13:20 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 13:20~13:45 Sex differences in pharmacokinetics ±èÀº¿µ(Áß¾Ó´ë¾à´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 13:45~14:10 Sex differences and the neurobiology of affective disorders ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 14:10~14:30 Sex differences and the neurobiology of schizophrenia ÀÌÁ¤¼®(º¸Çè°ø´Ü Àϻ꺴¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 13:20~13:45 Atypical antipsychotics ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 13:45~14:10 Antidepressant ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 14:10~14:30 Other psychotropic drugs À̴뺸(±¹¸³¹ý¹«º´¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 14:30~14:55 Premenstrual dysphoric disorder õÀºÁø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 14:55~15:20 Eating disorder ÀÌ»ó¹Î(°æÈñÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 15:20~15:40 Psychiatric disease in female cancer ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 14:30~15:05 Recent trend of treatment for schizophrenia ¼Á¤¼®(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 15:05~15:40 Updating news by recent article Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
ÈÞ½Ä 09¿ù 07ÀÏ 15:40~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 15:50~16:15 Acute management Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 16:15~16:40 Maintenance therapy ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ÄÁº¥¼ÇȦ 16:40~17:00 Specific populations ÀÓÀº¼º(½Å¼¼°èº´¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 15:50~16:15 TD or not TD: Dx and DDx ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 16:15~16:40 Pathophysiology of TD ¿ÀÈ«¼®(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 09¿ù 07ÀÏ ´ëȸÀÇ½Ç 16:40~17:00 New drugs: Valbenazine and deutetrabenazine Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)